Kidney Failure Articles & Analysis

Healionics Corporation, a private medical device company, announced today the completion of a $4.5M convertible note financing round. The financing supports the first human study, currently underway, of the company's innovative STARgraft vascular graft. In preclinical studies, STARgraft demonstrated improved ability to maintain blood flow compared to on-market vascular grafts, thereby offering ...

By Healionics

Xeltis has initiated the clinical trial for aXess, the first-ever restorative synthetic haemodialysis access graft. Several patients with kidney failure or advanced kidney disease requiring dialysis have already been successfully implanted as part of a European first-in-human trial to date. The aXess grafts enable early puncturing, or initiation of the dialysis, shortly after implanting. ...

By XELTIS BV

To learn how Xeltis’ restorative hemodialysis access graft, aXess, may be opening new horizons for patients with kidney failure, tune in the Visionary Endovascular and Vascular Education (VERVE) Symposium in Sidney, up to 4 December. In his talk on Saturday 4 December (10am AET), Professor Frans L. Moll, University Medical Center, Utrecht (NL) will explain how the Xeltis synthetic device ...

By XELTIS BV

Epinex Diagnostics, Inc., a private medical company that focuses on point-of-care diagnostic tests, announced today that Asad Zaidi, CEO and James McCarthy, Senior Vice President will present at the 19th annual BIO CEO & Investor Conference in New York, NY on Feb. 13, 2017 at 8:00 a.m. ET in the Conrad Room at the Waldorf Astoria New York. The company has developed three patented innovative ...

By Epinex Diagnostics Inc

QUANTA Dialysis Technologies Ltd (“QUANTA” or the “Company”), a medical technology company committed to making kidney care more accessible with its SC+ haemodialysis system, has released a new report that suggests people with kidney failure who wish to do home dialysis face unequal access across the UK. The Bridging the Gap report finds that failure to offer such treatment ...

By QUANTA Dialysis Technologies

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the progressive formation of fluid-filled cysts in the kidneys, often leading to complications, including hypertension, kidney stones, urinary tract infections, and eventually kidney failure. Affecting approximately 12 million people globally, ADPKD currently has no cure, and strategies to ...

By Bertin Technologies

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of charitable grants to establish or expand community-focused patient navigator programs. This is the second year of this unique program aimed at eliminating barriers to care for ...

By Aurinia Pharmaceuticals Inc.

The Ellipsys® Vascular Access System enables patients with kidney failure to start dialysis treatment sooner with fewer procedures, complications and interventions compared to surgery, according to several leading physicians who spoke at the recent meeting of the American Society of Diagnostic and Interventional Nephrology (ASDIN). Interventional radiologist Jeffrey Hull, M.D., was awarded ...

By Avenu Medical, Inc.

Exploratory analysis of the FIGARO-DKD study with finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, indicated a reduction in renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), as seen in the FIDELIO-DKD study Analysis of the FIDELIO-DKD study highlighted that early reduction of urine albumin-to-creatinine ratio (UACR) with ...

By Bayer AG

Global warming could be partly to blame for increases in some human and animal viral infections. A new Belgian study investigates the link between climate change and the recent increase in the human disease, nephropathia epidemica (NE), spread by rodents. The authors predict that NE could become a highly endemic disease in Belgium and neighbouring countries. 'Vector-borne' infections are ...

By European Commission, Environment DG

Healionics Corporation, a Seattle-based medical device company, today announced the appointment of Mike Connolly as Chief Executive Officer. Connolly brings 25 years of leadership in the medical device industry including extensive experience in both operating and venture investing roles. “We are fortunate to add a leader of Mike’s caliber,” said Andrew Marshall, Director and ...

By Healionics

Ace Therapeutics launches its cutting-edge in vivo models of diabetes mellitus. These models—chemically induced, genetically engineered, or diet-induced—have the potential to advance diabetes research by giving scientists the means to support the identification and development of novel treatment approaches. Diabetes mellitus, a chronic condition characterized by elevated blood ...

By Ace Therapeutics

Healionics Corporation, a Seattle-based medical device company, was awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) to develop new vascular grafts for dialysis use that overcome the major problem of clotting failure. Andrew Marshall, Ph.D., ...

By Healionics

Healionics Corporation, a Seattle-based medical device company, has received notice from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of a $1.7M Fast-Track Small Business Innovation Research (SBIR) grant in support of regulatory approval and a clinical study of STARgraftTM, its innovative synthetic vascular graft. Andrew Marshall, Healionics’ Chief Technology ...

By Healionics

Finerenone, a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is recommended by CHMP for marketing authorization for the treatment of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) CHMP opinion is based on the results of the Phase III FIDELIO-DKD study investigating the efficacy and safety of finerenone on kidney and cardiovascular outcomes in patients ...

By Bayer AG

- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 6, 2022-- Alnylam ...

By Alnylam Pharmaceuticals, Inc.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ (voclosporin) will be presented at the 2022 National Kidney Foundation Spring Clinical Meetings, taking place April 6-10, 2022 in Boston, Mass. ...

By Aurinia Pharmaceuticals Inc.

Despite available treatment options, many patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are progressing to kidney failure or premature death Kerendia (finerenone) is the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate positive kidney and cardiovascular (CV) outcomes in patients with CKD and T2D The approval is based on the ...

By Bayer AG

Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it will be carrying out an NIH-sponsored Phase I study of Bioflux-AI, Biotricity’s innovative artificial intelligence-driven (‘AI’) system of real-time monitoring and prediction technology, in subjects with ...

By Biotricity Inc.

A £1.1 million project to develop biodegradable stents for patients with severe vascular disease, which affects around one million people in the UK, has started thanks to Innovate UK funding. The unique project, a collaboration between the UK-based medical device company Arterius and the Translational Biomedical Research Centre (TBRC) at the University of Bristol, will develop a new type of ...

By Arterius Limited